Skip to main
  1. Stocks
  2. GRI Bio Inc
  3. Forecast
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is viewed favorably because GRI-0621 has already shown clinically meaningful IPF signals, including placebo-adjusted FVC gains of 99 ml as monotherapy and 139 ml with standard of care, plus a clean 12-week safety profile. The deeper biomarker package from 35 Phase 2a patients strengthens confidence that the drug is not merely symptomatic, but is acting through immune rebalancing, reduced lung injury, fibrosis resolution, and tissue repair across multiple assays. With IPF affecting about 140,000 U.S. patients, no debt, and $11 million in cash in Q2, the company has a differentiated lead asset and enough runway to pursue the next regulatory path.

Bears say

GRI Bio is exposed to substantial fundamental risk because its prospects depend on early-stage clinical assets that must still prove safety and efficacy, secure regulatory approvals, and ultimately achieve commercialization and reimbursement. The company also faces balance sheet and liquidity pressure, while macroeconomic conditions, biotech investor sentiment, and shifting consumer or government healthcare priorities can further undermine funding access and valuation. With competition intensifying and key programs such as GRI-0621 and GRI-0803 still dependent on clinical validation, the business remains highly uncertain and vulnerable to multiple execution failures.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

GRI Analyst Forecast & Price Prediction

Get the latest GRI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GRI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


GRI Analyst Forecast & Price Prediction

Get the latest GRI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GRI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GRI stock data and trends